All In Biotech

Drug Trial Radar · NCT05646706

A Research Study to See How Semaglutide Helps People With Excess Weight, Lose Weight (STEP UP)

Effect and Safety of Semaglutide 7.2 mg Once-weekly in Participants With Obesity

Last checked: Nov 20, 2026Latest source record: Apr 23, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingPhase 3. Randomized with 1,407 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

1,407

Actual

Start

Jan 4, 2023

Primary completion

Oct 30, 2024

Study completion Nov 26, 2024

Sponsor

Lead sponsor
Novo Nordisk A/SNovo Nordisk (NVO)
Sponsor type
Industry
First posted
Dec 12, 2022

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This study will look at how much weight participants will lose from the start to the end of the study. The weight loss in participants taking the investigational high dose of semaglutide will be compared to the weight loss in people taking "dummy" medicine and a lower dose of semaglutide. In addition to taking the medicine, participants will have talks with study staff about healthy food choices and how to be more physically active. Participants will either get semaglutide or "dummy" medicine. Which treatment participants get is decided by chance. Participants are more likely (4 out of 5) to get semaglutide than the "dummy" medicine. The study medicine will be injected briefly, under skin, with a thin needle, typically in the stomach, thighs, or upper arms. In the first part of the study, participants will get one injection once a week until they reach the planned dose. The second part of the study, which might last a couple of months, is a transition period, where participant will get three injections, taken right after each other, once a week. The duration of the study intervention (trial product and lifestyle intervention) will be 72 weeks followed by a 9-week follow-up period without study interventions.

Conditions

  • Obesity

Interventions

  • SemaglutideDrug

    Participants will receive once-weekly s.c. injections of semaglutide in escalating doses (0.25 mg, 0.5 mg, 1.0 mg, 1.7 mg, 2.4 mg and 7.2 mg) every fourth week. Treatment was continued on the maintenance dose of 7.2 mg once-weekly for an additional 52 weeks. Injections may be administered in the thigh, abdomen, or upper arm, at any time of day irrespective of meals.

  • SemaglutideDrug

    Participants will receive once-weekly s.c. injections of semaglutide in escalating doses (0.25 mg, 0.5 mg, 1.0 mg, 1.7 mg, and 2.4 mg) every fourth week. Treatment was continued on the maintenance dose of 2.4 mg once-weekly for an additional 52 weeks. Injections may be administered in the thigh, abdomen, or upper arm, at any time of day irrespective of meals.

  • PlaceboDrug

    Participants will receive once-weekly s.c. injection of placebo matched to semaglutide for 72 weeks. Injections may be administered in the thigh, abdomen, or upper arm, at any time of day irrespective of meals.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Semaglutide 7.2 mg Versus Placebo: Relative Change in Body WeightTime frame: Baseline (week 0), End of treatment (week 72)
  2. Semaglutide 7.2 mg Versus Placebo: Number of Participants Who Achieve Body Weight Reduction Greater Than or Equal to (>=) 5% (Yes/no)Time frame: At week 72

Locations

107 sites in 12 countries. Site status is shown where the registry gives one.

  • Univ of Alabama Birmingham

    Birmingham, Alabama

  • Chambliss Clinical Trials, LLC

    Montgomery, Alabama

  • Healthscan Clinical Trials,LLC.

    Montgomery, Alabama

  • Diablo Clinical Research, Inc.

    Walnut Creek, California

  • Jacksonville Ctr For Clin Res

    Jacksonville, Florida

  • Florida Inst For Clin Res LLC

    Orlando, Florida

  • Florida Institute For Clinical Research LLC

    Orlando, Florida

  • East West Med Res Inst

    Honolulu, Hawaii

  • Midwest Inst For Clin Res

    Indianapolis, Indiana

  • AMC Community Endocrinology

    Albany, New York

  • University of North Carolina

    Chapel Hill, North Carolina

  • PharmQuest Life Sciences LLC

    Greensboro, North Carolina

  • Medical University Of South Carolina

    Charleston, South Carolina

  • Amarillo Med Spec LLP

    Amarillo, Texas

  • Elligo Clin Res Centre

    Austin, Texas

  • Velocity Clin Res, Dallas

    Dallas, Texas

  • UT Southwestern Medical Center-CRU

    Dallas, Texas

  • DCOL Ctr for Clin Res

    Longview, Texas

  • Sugar Lakes Family Practice PA

    Sugar Land, Texas

  • National Clin Res Inc.

    Richmond, Virginia

  • Selma Medical Associates

    Winchester, Virginia

  • Medical centre Zdrave 1 OOD

    Kozloduy, Bulgaria

  • Medical center Hippocrates Lukovit EOOD

    Lukovit, Bulgaria

  • IPMC - Dr. Elizabeta Dimitrova

    Petrich, Bulgaria

  • Medical center Smolyan clinical research OOD

    Smolyan, Bulgaria

  • DCC Ascendent OOD

    Sofia, Bulgaria

  • SGHAT Dr. Shterev EOOD

    Sofia, Bulgaria

  • Acibadem City Clinic UMHAT Tokuda EAD, Endocrinology

    Sofia, Bulgaria

  • Medical Centre Medical Arts Medico-dental centre

    Sofia, Bulgaria

  • Medical Center Medical Plus EOOD

    Varna, Bulgaria

  • AIPSMC Dr. Evelina Zlatanova EOOD

    Varna, Bulgaria

  • Ocean West Research Clinic

    Surrey, British Columbia, Canada

  • Nova Scotia Health Authority

    Halifax, Nova Scotia, Canada

  • Nova Scotia Hlth Halifax

    Halifax, Nova Scotia, Canada

  • Premier Clinical Trial Research Network (PCTRN)

    Hamilton, Ontario, Canada

  • Wharton Med Clin Trials

    Hamilton, Ontario, Canada

  • Wharton Medical Clinic Clinical Trials (Hamilton)

    Hamilton, Ontario, Canada

  • Hamilton Med Res Group

    Hamilton, Ontario, Canada

  • Milestone Research

    London, Ontario, Canada

  • Ordinace praktického lékaře

    Benátky Na Jizerou, Czechia

Showing 40 of 107 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.